Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
to evaluate the wall-to-lumen ratio (WLR) of retinal arterioles in hypertensive patients with retinal vein occlusion (RVO) before and after dexamethasone intravitreal implant 0.7 mg (DEX) compared to a matched control group of normal eyes in non-hypertensive subjects.
change of outer arteriolar diameter [ Time Frame: the primary endpoint was at 6 months ]
change of inner arteriolar diameter [ Time Frame: the primary endpoint was at 6 months ]
Secondary Outcome Measures
Secondary outcome measures were as follows: adverse ocular events; mean change in visual acuity; and mean change in central macular thickness. [ Time Frame: Outcomes were analyzed at 4 intermediate time points: 30, 60, 90, and 150 days. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
ability to provide written informed consent and comply with study assessments for the full duration of the study;
age > 20 years;
decreased visual acuity as a result of clinically detectable ME associated with either CRVO or BRVO;
the duration of macular edema was required to be between 4 and 24 weeks for both CRVO and BRVO;
retinal thickness in the central subfield (as measured using optical coherence tomography) had to be > 350 µm in the study eye.
the exclusion criteria were as follows: diabetes; previous intravitreal anti-VEGF therapy or intravitreal steroid therapy; previous photodynamic therapy or focal laser; active retinal or optic disc neovascularization; active or history of choroidal neovascularization; presence of rubeosis iridis; any active infection; glaucoma, current ocular hypertension, or a history of steroid-induced intraocular pressure (IOP) increase in either eye; or concurrent eye disease in the study eye that could compromise visual acuity (e.g., choroidal neovascularization, diabetic retinopathy, epiretinal membrane).